- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00392782
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies
RATIONALE: Giving total-body irradiation and chemotherapy, such as fludarabine and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin and removing the T cells from the donor cells before transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well a donor stem cell transplant works in treating patients with myeloid cancer or other disease.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Determine the incidence of disease-free survival at 1 year in patients with acute or chronic myeloid leukemias undergoing T-cell-depleted hematopoietic stem cell transplantation from HLA-C mismatched, unrelated donors.
Secondary
- Determine the incidence of disease relapse at 1 year in patients treated with this regimen.
- Determine the incidence and severity of acute graft-vs-host disease (GVHD) at 100 days and chronic GVHD at 1 year in these patients.
- Determine the incidence of graft failure at day 100.
- Determine the transplant-related mortality of these patients at 1 year.
- Determine the overall survival of these patients at 1 year.
OUTLINE: This is a prospective, multicenter study. Patients are stratified according to killer-cell immunoglobulin-like receptors (KIR) epitope mismatch (yes [experimental] vs no [control]).
- Myeloablative preparative regimen: Patients undergo total body irradiation twice daily on days -10 and -9 and receive thiotepa intravenously (IV) over 4 hours on days -8 and -7, fludarabine phosphate IV over 30-60 minutes on days -7 to -3, and antithymocyte globulin IV over 4-6 hours on days -5 to -2.
- Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo filgrastim (G-CSF)-mobilized, T-cell-depleted, CD34+-selected allogeneic PBSC transplantation on day 0.
After completion of study treatment, patients are followed periodically for at least 1 year.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Winship Cancer Institute of Emory University
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202-5289
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210-1240
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin Cancer Center
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Midwest Children's Cancer Center at Children's Hospital of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Primary acute myeloid leukemia (AML)
- First complete remission (CR) with high risk features as defined by: failure to achieve remission by day 21 after induction chemotherapy, or the presence of chromosomal abnormalities involving any of the following: -5/de (5q), -7/del(7q), inversion 3q, abnormalities of 11q23, 20q, 21q, del(9q), translocation 6;9, translocation 9;22, abnormalities of 17p, or complex karyotype with > or = 3 abnormalities. Complete remission is defined as < 5% blasts in the marrow.
- Second CR or subsequent in remission
- Refractory or relapsed disease with absolute peripheral blood blasts < 2000/mcL
- Secondary AML in remission or relapse
Chronic myelogenous leukemia (CML) in accelerated or blast phase
Accelerated phase is defined by any one of the following:
- Blasts 10% to 19% of peripheral blood white cells or bone marrow cells
- Peripheral blood basophils at least 20%
- Persistent thrombocytopenia (<100 x 10^9/L) unrelated to therapy, or persistent thrombocytosis (>1000 x 10^9/L) unresponsive to therapy
- Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy
- Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase CML)
- Resistance to tyrosine kinase inhibitors (imatinib or other) defined as no complete cytogenetic response even if the above criteria are not met.
Blast phase is defined by either of the following:
- Blasts 20% or more of peripheral blood white cells or bone marrow cells
- Extramedullary blast proliferation
- Large foci or clusters of blasts in bone marrow biopsy
- Primary myelodysplastic syndrome (MDS) with an IPSS score >1
- Secondary MDS with any international prostate symptom score (IPSS)
- Age ≤60 years
- Co-Morbidity score 0-2
- At least 35 days following start of preceding leukemia induction therapy
Exclusion Criteria:
- Patients for whom a suitable HLA genotypically identical sibling or fully matched HLA-A, -B, -C, and -DRB1 unrelated donor is available.
- Patients greater than 60 years of age.
- Hypersensitivity to thymoglobulin.
- Symptomatic uncontrolled coronary artery disease or congestive heart failure.
- Hepatic disease with transaminases or bilirubin > 2 times upper limit of normal (ULN) except for isolated hyperbilirubinemia attributed to Gilbert's syndrome.
- Severe hypoxemia with room air - Partial Pressure of Oxygen in Arterial Blood - (PAO2) < 70, supplemental oxygen-dependence, or carbon monoxide diffusing capacity (DLCO) < 50% predicted.
- Impaired renal function with creatinine > 2 times upper limit of normal (ULN) or creatinine clearance measured by 24-hour urine collection < 50% normal for age, gender, and weight.
- Patients with central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy.
- Patients who are human immunodeficiency virus (HIV) seropositive.
- Patients who are pregnant or breast-feeding.
- Patients with active infections that are untreated, or failing to respond to appropriate therapy.
- Karnofsky performance status < 50%.
- Prior allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical cord blood transplant.
- Inability to provide informed consent.
- Co-morbidity score >2
- Less than 35 days from start of previous leukemia induction therapy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Natural Killer Cell Kir Epitope
|
Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2.
The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
Andere Namen:
Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
Andere Namen:
Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
Peripheral Blood Stem Cell (PBSC) Infusion.
All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal.
PBSC is infused via a central venous catheter using blood infusion tubing.
Andere Namen:
The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Incidence of Disease-free Survival
Zeitfenster: 1 Year
|
Number of patients alive and without disease at 1 year after transplant.
|
1 Year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Incidence of Disease Relapse
Zeitfenster: 1 Year
|
Number of patients with disease at 1 year.
|
1 Year
|
Incidence of Grade II-IV Acute Graft-vs-host Disease (GVHD)
Zeitfenster: Day 100
|
Number of patients with grade II-IV acute graft-versus-host disease at Day 100 post transplant.
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Grade I=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening.
|
Day 100
|
Incidence of Chronic Graft-versus-host Disease (GVHD)
Zeitfenster: 1 Year
|
Number of patients with chronic graft-versus-host disease at 1 year post transplant.
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.
Grade I=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening.
Chronic GVHD is an extension of acute GVHD.
|
1 Year
|
Incidence of Graft Failure
Zeitfenster: Day 100
|
Number of patients with graft failure is defined by lack of neutrophil engraftment by 100 days after transplant in patients surviving a minimum of 14 days.
|
Day 100
|
Transplant-related Mortality
Zeitfenster: 1 Year
|
Number of patients with treatment related death at 1 year post transplant.
|
1 Year
|
Overall Survival
Zeitfenster: 1 Year
|
Number of patients who were deceased at 1 year post transplant.
|
1 Year
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- de novo myelodysplastische Syndrome
- zuvor behandelte myelodysplastische Syndrome
- sekundäre myelodysplastische Syndrome
- akute myeloische Leukämie bei Erwachsenen mit 11q23 (MLL)-Anomalien
- akute myeloische Leukämie bei Erwachsenen mit inv(16)(p13;q22)
- akute myeloische Leukämie bei Erwachsenen mit t(15;17)(q22;q12)
- akute myeloische Leukämie bei Erwachsenen mit t(16;16)(p13;q22)
- akute myeloische Leukämie bei Erwachsenen mit t(8;21)(q22;q22)
- sekundäre akute myeloische Leukämie
- Akute myeloische Leukämie im Kindesalter in Remission
- Chronische myeloische Leukämie im Kindesalter
- rezidivierende akute myeloische Leukämie bei Erwachsenen
- akute myeloische Leukämie bei Erwachsenen in Remission
- chronische myeloische Leukämie in der Blastenphase
- rezidivierende chronische myeloische Leukämie
- Chronische myeloische Leukämie in beschleunigter Phase
- rezidivierende akute myeloische Leukämie im Kindesalter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen nach histologischem Typ
- Neubildungen
- Erkrankung
- Erkrankungen des Knochenmarks
- Hämatologische Erkrankungen
- Krebsvorstufen
- Syndrom
- Myelodysplastische Syndrome
- Leukämie
- Präleukämie
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Myeloablative Agonisten
- Fludarabin
- Fludarabinphosphat
- Thiotepa
- Antilymphozyten-Serum
Andere Studien-ID-Nummern
- 2004UC035
- UMN-MT2004-04 (Andere Kennung: Blood and Marrow Transplantation Program)
- UMN-0405M59662 (Andere Kennung: IRB, University of Minnesota)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Myelodysplastische Syndrome
-
University of Colorado, DenverRekrutierungKlinefelter-Syndrom | Trisomie X | XYY-Syndrom | XXXY- und XXXXY-Syndrom | Xxyy-Syndrom | Xyyy-Syndrom | Xxxx-Syndrom | Xxxxx-Syndrom | Xxxyy-Syndrom | Xxyyy-Syndrom | Xyyyy-Syndrom | Männchen mit GeschlechtschromosomenmosaikVereinigte Staaten
-
Riphah International UniversityAbgeschlossen
-
Riphah International UniversityAbgeschlossen
-
Shaare Zedek Medical CenterUnbekanntPrämenstruelles Syndrom-PMS
-
Esra ÖZERKTO Karatay UniversityRekrutierungPrämenstruelles Syndrom-PMSTruthahn
-
Assistance Publique - Hôpitaux de ParisRekrutierungIntensivstation-Syndrom | Pädiatrisches Post-Intensivpflege-SyndromFrankreich
-
Riphah International UniversityRekrutierungUpper-Cross-SyndromPakistan
-
Cairo UniversityNoch keine Rekrutierung
-
Cairo UniversityRekrutierung
-
Riphah International UniversityRekrutierungUpper-Cross-SyndromPakistan
Klinische Studien zur anti-thymocyte globulin
-
Wright State UniversitySanofi; University of Nebraska; University of Arizona; The Methodist Hospital Research... und andere MitarbeiterAbgeschlossenNierenerkrankung im Endstadium | NierenversagenVereinigte Staaten
-
M.D. Anderson Cancer CenterAbgeschlossenChronischer lymphatischer Leukämie | Myelodysplastisches Syndrom | Akute myeloische LeukämieVereinigte Staaten
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AbgeschlossenMultiples Myelom und Plasmazell-NeoplasmaVereinigte Staaten
-
Genzyme, a Sanofi CompanyAbgeschlossenMyelodysplastische SyndromeVereinigte Staaten, Kanada
-
Hospital de Clinicas de Porto AlegreAbgeschlossenImmunsuppression | Nierentransplantation; KomplikationenBrasilien
-
Universitätsklinikum Hamburg-EppendorfAbgeschlossenAkute myeloische Leukämie | Akute lymphatische LeukämieDeutschland
-
European Institute of OncologyIstituto Clinico HumanitasBeendet
-
Swedish Medical CenterGenzyme, a Sanofi CompanyAbgeschlossenImmunsuppression | NierentransplantationVereinigte Staaten
-
Assistance Publique - Hôpitaux de ParisUnbekannt
-
Ann & Robert H Lurie Children's Hospital of ChicagoUnbekanntSchwere ImmunschwächekrankheitenVereinigte Staaten